CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,954 enrolled
Drug / intervention
LABA and the LAMA tiotropium (LABA-TIO) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03376295
NCT03376295N/ACompleted

Comparative Effectiveness of Combination Therapies in COPD

Boehringer Ingelheim·observational·Posted Dec 18, 2017·Updated Jul 24, 2019

In Brief

An observational study evaluating LABA and the LAMA tiotropium (LABA-TIO) and LABA and an ICS (LABA-ICS) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 3,954 participants across 1 site.

Detailed Summary

To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium (LABA-TIO)) compared with the combination of a LABA and an ICS (LABA-ICS) on the time to COPD exacerbation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 18, 2017
Enrollment StartDec 1, 2017
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 8.5 years ago

Interventions

LABA and the LAMA tiotropium (LABA-TIO)drug

combinational drug

LABA and an ICS (LABA-ICS)drug

combinational drug